Sunitinib Induced Cytopenia in Metastatic RCC

Guidelines in Metastatic Rcc

primary endpoint, but also the secondary endpoints that should corroborate the primary endpoint, will stand. This approach is based on the Prentice principle, which states that a result has a higher probability of being truly positive if other related endpoints are also positive 1. An advantage in progression-free survival (pfs) has more chance of being true if a statistically significant advan...

Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine- Refractory Metastatic RCC

Sustained long-term clinical and radiological response with sunitinib for metastatic renal-cell carcinoma (RCC)

The authors herein report the case of a 67-yearold woman with metastatic renal-cell carcinoma (RCC), who has had a sustained clinical and stable radiological response to long-term therapy with an oral multi-targeted tyrosine kinase inhibitor (TKI), sunitinib with minimal lasting toxicity.

Sunitinib Induced Immune Thrombocytopenia

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...

Sorafenib in the Management of Metastatic Rcc

Until the advent of targeted therapies, interferon alfa and interleukin-2 represented the standards of care for patients with metastatic renal cell carcinoma (mrcc). Since 2006, six randomized controlled trials have demonstrated the efficacy of five novel targeted therapies in primarily clear-cell mrcc patients 1–6. First, in previously untreated patients (n = 750), Motzer et al. showed that, a...